Diasorin SpAMIL:DIA -3.14%69 Days Payable is 91.44 as of Dec. 2025, which is 1% above its 10-year median of 90.35. GuruFocus rates MIL:DIA with a GF Score™ of 69/100 and a GF Value™ of €90.16 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 190 Medical Diagnostics & Research companies, Diasorin SpA ranks better than 61.58% on this metric.
The historical rank and industry rank for Diasorin SpA's Days Payable or its related term are showing as below:
MIL:DIA'
s Days Payable Range Over the Past 10 Years
Min: 66.42 Med: 90.35 Max: 102.28
Current: 91.04
During the past 13 years, Diasorin SpA's highest Days Payable was 102.28. The lowest was 66.42. And the median was 90.35.
MIL:DIA's Days Payable is ranked better than 61.58% of 190
companies
in the Medical Diagnostics & Research industry
Industry Median: 67.275
vs MIL:DIA: 91.04
Diasorin SpA's Days Payable
increased
from Dec. 2024 (86.71) to Dec. 2025 (91.44).
It may suggest that Diasorin SpAdelayed paying its suppliers.
Diasorin SpA Days Payable Related Terms
Diasorin SpA Days Payable Historical Data
* Premium members only.
The historical data trend for Diasorin SpA's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIL:DIA vs TMO, DHR, IDXX: Days Payable Comparison
For the Diagnostics & Research subindustry, Diasorin SpA's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diasorin SpA Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Diasorin SpA's Days Payable distribution charts can be found below:
* The bar in red indicates where Diasorin SpA's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Diasorin SpA's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diasorin SpA (MIL:DIA) has a Days Payable of 91.44 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Diasorin SpA and its competitors. This is near median its historical median of 90.35. Over the past decade, Diasorin SpA's Days Payable has ranged from 66.42 to 102.28. According to the industry distribution chart, Diasorin SpA ranks #73 out of 190 companies in the Medical Diagnostics & Research industry, placing it in the top 38.4%.
Is Diasorin SpA's Days Payable too high?
Diasorin SpA's current Days Payable of 91.44 is near median its 10-year median of 90.35. Over the past 10 years, this metric has ranged from a low of 66.42 to a high of 102.28. The Medical Diagnostics & Research industry median Days Payable is 67.28. Diasorin SpA's value of 91.44 is 35.9% above this industry median. Based on the distribution chart, Diasorin SpA ranks #73 out of 190 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Diasorin SpA has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Diasorin SpA's Days Payable compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Diasorin SpA ranks #73 out of 190 companies for Days Payable. This puts Diasorin SpA in the upper half of its industry. The industry median Days Payable is 67.28. Diasorin SpA's value of 91.44 is 35.9% above this benchmark. Historically, Diasorin SpA's own Days Payable has ranged from 66.42 to 102.28 over the past decade. While the company's 10-year median is 90.35 vs. the industry median of 67.28, Diasorin SpA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 67.28, based on 190 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Diasorin SpA's current Days Payable of 91.44 is 35.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Diasorin SpA and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 67.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diasorin SpA's current Days Payable is 91.44, which is near median its own 10-year median of 90.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diasorin SpA stock overvalued right now?
Based on GuruFocus' analysis, Diasorin SpA (MIL:DIA) is currently considered Modestly Undervalued. The stock's GF Value™ is €90.16, compared to a current price of €67.76 — trading 24.8% below its estimated fair value. The current Days Payable is 91.44, which is near median its 10-year median of 90.35 and 35.9% above the Medical Diagnostics & Research industry median of 67.28. Diasorin SpA's overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Diasorin SpA (MIL:DIA), the current Days Payable is 91.44 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diasorin SpA (MIL:DIA) Overvalued in 2026?
Based on GuruFocus' analysis, Diasorin SpA stock appears to be undervalued.
The current stock price of €67.76 is trading 24.8% below its estimated GF Value™ of €90.16.
GuruFocus considers Diasorin SpA to be Modestly Undervalued.
Key valuation signals for MIL:DIA:
Days Payable: 91.44 (near median its 10-year median of 90.35)
GF Value™: €90.16 vs. price of €67.76 (24.8% below fair value)
Industry Position: 35.9% above the Medical Diagnostics & Research median (#73 of 190)
No single metric tells the full story. See the MIL:DIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diasorin develops and manufactures a broad portfolio of in vitro diagnostics for detecting pathogens and sample contamination from the human body, as well as for use in industrial settings, such as food and water contamination testing. The company operates three segments: immunodiagnostics (69% of sales), molecular diagnostics (16%), and licensed technologies (14%). Diasorin was an important manufacturer of covid tests, which boosted its profits during the pandemic, but this segment's importance has decreased over the years, and in 2025, it accounted for only 1% of total sales.
69GF Score
Get the complete analysis for MIL:DIA
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:DIA has been successfully added to your 
